ZAXINE 550 MG — DIN 02410702
RIFAXIMIN : 550 MG · SALIX PHARMACEUTICALS INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is ZAXINE?
ZAXINE 550 MG contains RIFAXIMIN : 550 MG. It is listed in the Health Canada Drug Product Database under DIN 02410702, held by SALIX PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZAXINE used for?
Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults; reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rifaximin cost around the world?
Rifaximin is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Iceland | max wholesale | 4 | 6 | ISK███.██ |
| Romania | max producer price | 4 | 4 | RON███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
16 pack listings across 14 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Rifaximin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 550 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 60 tablets. |
| Storage | Not explicitly detailed in provided text (section 11 header present but content truncated), typically 15-30°C for tablets. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Rifaximin |
|---|---|
| ATC code | A07AA11 |
| AHFS class | 08:12.28.30 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02410702 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2410702 |
| Brand name | ZAXINE |
| Generic / active ingredient | RIFAXIMIN : 550 MG |
| Market authorization holder | SALIX PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | A07AA11 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07AA |
| Current status | MARKETED |
| Status date | 07-Nov-2013 |
| Original market date | 2013-11-07 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
HE: 550 mg twice daily. IBS-D: 550 mg three times daily for 14 days. Can be taken with or without food. Tablets should be swallowed whole.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any ingredient in the formulation.
Warnings and precautions
Not for systemic infections. Clostridium difficile-associated disease (CDAD) reported. Severe cutaneous adverse reactions (SJS/TEN) reported. Increased exposure in hepatic impairment.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC A07AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Vancomycin | JAMP VANCOMYCIN · PMS-VANCOMYCIN · PMSC-VANCOMYCIN · VANCOCIN | 8 | 4 | Yes |
| Nystatin | DOM-NYSTATIN SUSPENSION · FTP-NYSTATIN · JAMP-NYSTATIN ORAL SUSPENSION USP · MYCOSTATIN ORAL SUSPENSION 100000IU · +11 more | 15 | 3 | Yes |
| Fidaxomicin | DIFICID | 1 | 1 | Yes |
| Paromomycin | HUMATIN | 1 | 1 | Yes |
| Rifaximin | ZAXINE | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ZAXINE called?
The same molecule, Rifaximin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Xifaxan | Latin | Australia, Iceland, Saudi Arabia, South Africa |
| Normix | Latin | Iceland |
| Fatroximin I.U. | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.